Zencurix Utilizes Its Products to Discover Biomarkers for Differentiating Endometrial Cancer Types

[Asia Economy Reporter Hyungsoo Park] GenCurix announced on the 18th that its droplet digital PCR (ddPCR) testing method and products were utilized in a study by obstetrics and gynecology and pathology researchers at a university hospital on mutation diagnosis of endometrial cancer.

The research team published a paper titled "Evaluation of the Utility of a ddPCR-Based Test for Detecting Pathogenic Mutations in the POLE Gene Related to Endometrial Cancer" in the international gynecologic oncology journal, Journal of Gynecologic Oncology.

Through the study, the ddPCR method successfully detected the five most frequent pathogenic hotspot mutations in the POLE gene of endometrial cancer. The ddPCR approach, which reduces cost and time while demonstrating high accuracy, is evaluated as capable of diagnosing major types of endometrial cancer.

A GenCurix official stated, "Classifying endometrial cancer patient types is important for establishing treatment plans and predicting prognosis," adding, "Endometrial cancer is the most common gynecologic cancer due to factors such as westernized dietary habits."

They achieved results detecting mutations that were previously difficult to identify due to low frequency using GenCurix products. By utilizing ddPCR testing and GenCurix diagnostic kits, it is possible to rapidly and accurately detect POLE gene mutations and determine molecular biological subtypes in endometrial cancer patients.

The company representative explained, "Our diagnostic kits were effectively used in discovering protein immunohistochemical biomarkers for genetic classification of endometrial cancer," and added, "We will pursue market leadership through launching various companion diagnostic products based on ddPCR diagnostic equipment and through research collaborations."

This content was produced with the assistance of AI translation services.